Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues

Histopathology

Volumn 47, Issue 6, 2005, Pages 602-610

  Soilleux, E J ^a   Turley, H ^a   Tian, Y M ^b   Pugh, C W ^b   Gatter, Kevin C ^a   Harris, A L ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cancer; FIH; HIF 1 ; HIF 2 ; PHD

Indexed keywords

FACTOR INHIBITING HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MONOCLONAL ANTIBODY; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE 1; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE 2; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE 3; PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL NUCLEUS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEUKOCYTE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TISSUE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DIOXYGENASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PROCOLLAGEN-PROLINE DIOXYGENASE; REPRESSOR PROTEINS; TISSUE DISTRIBUTION; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 28844470450     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02280.x     Document Type: Article

References (21)

1. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 1996; 76; 839-885.
2. Hockel M, Schlenger K, Hockel S et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int. J. Cancer 1998; 79; 365-369.
3. Stadler P, Becker A, Feldmann HJ et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44; 749-754.
4. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc. Natl Acad. Sci. USA 1993; 90; 2423-2427.
5. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004; 5; 343-354.
6. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 2003; 29; 297-307.
7. 2 tension. Proc. Natl Acad. Sci. USA 1995; 92; 5510-5514.
8. Hewitson KS, McNeill LA, Schofield CJ. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr. Pharm. Des. 2004; 10; 821-833.
9. del Peso L, Castellanos MC, Temes E et al. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J. Biol. Chem. 2003; 278; 48690-48695.
10. Lando D, Peet DJ, Gorman JJ et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16; 1466-1471.
11. Hewitson KS, McNeill LA, Riordan MV et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 2002; 277; 26351-26355.
12. Talks KL, Turley H, Gatter KC et al. The expression and distribution of the hypoxia-inducible factors HTF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 2000; 157; 411-421.
13. Lieb ME, Menzies K, Moschella MC, Ni R, Taubman MB. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem. Cell Biol. 2002; 80; 421-426.
14. Oehme F, Ellinghaus P, Kolkhof P et al. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem. Biophys. Res. Commun. 2002; 296; 343-349.
15. Huang J, Zhao Q, Mooney SM, Lee FS. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J. Biol. Chem. 2002; 277; 39792-39800.
16. Metzen E, Berchner-Pfannschmidt U, Stengel P et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J. Cell Sci. 2003; 116; 1319-1326.
17. Appelhoff RJ, Tian Y-M, Raval RR et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 2004; 279; 38458-38465.
18. Stolze IP, Tian Y-M, Appelhoff RJ et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J. Biol. Chem. 2004; 279; 42719-42722.
19. Wiesener MS, Turley H, Allen WE et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998; 92; 2260-2268.
20. Trabold O, Wagner S, Wicke C et al. Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. Wound Repair Regen. 2003; 11; 504-509.
21. Groulx I, Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 2002; 22; 5319-5336.